Best’s Insurance Law Podcast Discusses Handling Commercial Vehicle Accident Claims

OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best and Best’s Insurance Professional Resources have released the latest installment of the Best's Insurance Law Podcast series, which examines timely claims and insurance issues from a legal perspective.

This episode discusses the investigation process for commercial vehicle accidents and the potential for fraudulent claims.

The podcast features Adjuster James Barbieri, president and chief executive officer of Claims Advantage Inc., in Georgia. Barbieri is a certified insurance fraud investigator (CIFI) and adjuster, and has been conducting insurance fraud investigations for over 30 years.

Claims Advantage Inc. is a qualified member of Best's Insurance Professional Resources, a claims industry resource that has featured qualified legal counsel, independent insurance adjusting services and expert service providers since 1929.

Listen or subscribe to the Insurance Law Podcast.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in New York, London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2020 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005584/en/

Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
[email protected]

Jim Peavy
Director, Communications
+1 908 439 2200, ext. 5644
[email protected]

Source: AM Best

You May Also Be Interested In

• Sensorion Reports 2026 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
• Oticon Medical Launches SmartCharger for the Ponto 5 Family
• OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting